Epplin J J, Wujek R A, Laughlin L D
Litchfield Family Practice Center, IL 62056.
J Am Board Fam Pract. 1988 Apr-Jun;1(2):87-90.
To determine the safety and efficacy of the use of intravenous streptokinase in a 110-bed rural community hospital, we studied 28 consecutive patients with clinical and ECG evidence of acute myocardial infarction. Twenty (74 percent) of the 27 patients who had cardiac catheterization after treatment with intravenous streptokinase were found to have a patent artery supplying the infarcted area. One patient (3.5 percent) died of intractable heart failure, 2 (7 percent) had ventricular fibrillation, and 9 (32 percent) had ventricular tachycardia. Six patients (21 percent) had minor bleeding problems, and 1 developed a pseudoaneurysm at the catheterization site. We maintained close communication with a consulting cardiology group who provided additional medical or surgical therapy in a tertiary medical center for patients who needed it. We believe that intravenous streptokinase can be safely and effectively used in a rural community hospital.
为确定在一家拥有110张床位的农村社区医院使用静脉注射链激酶的安全性和有效性，我们研究了28例有急性心肌梗死临床和心电图证据的连续患者。在接受静脉注射链激酶治疗后接受心脏导管插入术的27例患者中，有20例（74%）被发现梗死区域的供血动脉通畅。1例患者（3.5%）死于顽固性心力衰竭，2例（7%）发生心室颤动，9例（32%）发生室性心动过速。6例患者（21%）有轻微出血问题，1例在导管插入部位形成假性动脉瘤。我们与一个咨询心脏病学团队保持密切沟通，该团队为有需要的患者在三级医疗中心提供额外的内科或外科治疗。我们认为静脉注射链激酶可以在农村社区医院安全有效地使用。
